Insmed Incorporated (INSM)
INSM moved a median of -0.08% 30 minutes after news, and +0.10% by the close. How INSM actually reacts to news — the realized, point-in-time move the market made, measured across 701 labeled events over the last three years with zero look-ahead.
INSM’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.03% | 47% | 700 |
| 30-min | -0.08% | 45% | 701 |
| 60-min | +0.12% | 53% | 701 |
| to close | +0.10% | 51% | 693 |
| Middle 50% of INSM reactions | -0.77% to +0.82% |
|---|---|
| Median reaction (30-min) | -0.08% |
| Measured reactions | 701 |
Half of all Insmed Incorporated news events land between -0.77% and +0.82% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How INSM reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 13 | +0.19% | 54% | -0.96% |
| Coverage initiations | 42 | -0.79% | 38% | -0.14% |
| Rating reiterations | 198 | -0.14% | 47% | +0.35% |
| Price-target raises | 73 | +0.09% | 52% | +0.52% |
| Price-target cuts | 11 | -0.41% | 36% | -0.13% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 1 further class was observed with fewer than 10 measured events and is not published. See how INSM ranks against every other measured name →
That’s how INSM usually reacts — get an email when it moves on news →Email me when INSM moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to INSM's baseline. Nothing else.
Recent INSM events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Insmed Features the Global Phase 3 PALM Clinical Development Program Evaluating Treprostinil Palmitil Inhalation Powder (TPIP) at CHEST 2026 | Press release | PR Newswire | +0.83% | -0.05% | |
| Insmed to Present New Data Across Its Respiratory Portfolio at CHEST 2026 and IDWeek 2026 | Press release | PR Newswire | -1.01% | +0.41% | |
| Form 8-K INSMED Inc For: Oct 05 | SEC filing · Form 8-K | SEC EDGAR | +1.04% | -1.58% | |
| Insmed Announces CFO Transition | Press release | PR Newswire | +1.04% | -1.58% | |
| FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027 | Press release | PR Newswire | -0.92% | -1.67% | |
| Insmed Expands Community Impact During Fifth Annual Global Day of Good | Press release | PR Newswire | +0.04% | +2.15% | |
| Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | Press release | PR Newswire | +0.77% | +0.23% | |
| Insmed to Present Data Across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE® (amikacin liposome inhalation suspension) Results From Phase 3b ENCORE Study at the European Respiratory Society Congress 2026 | Press release | PR Newswire | -1.00% | -0.11% | |
| Insmed to Present at September 2026 Investor Conferences | Press release | PR Newswire | +0.37% | +1.22% | |
| BRINSUPRI® (brensocatib) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients With Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease | Press release | PR Newswire | -0.21% | -0.84% | |
| Form 10-Q INSMED Inc For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +3.09% | +4.37% | |
| Form 8-K INSMED Inc For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +3.09% | +4.37% | |
| Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Update | Press release | PR Newswire | +3.09% | +4.37% | |
| Insmed to Host Second-Quarter 2026 Financial Results Conference Call on Thursday, August 6, 2026 | Press release | PR Newswire | +0.45% | +1.52% | |
| Form 8-K INSMED Inc For: Jul 16 | SEC filing · Form 8-K | SEC EDGAR | -3.18% | -2.25% | |
| Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension | Press release | PR Newswire | -3.18% | -2.25% | |
| Insmed Appoints Samuele Butera as Senior Vice President, General Manager, Global Respiratory | Press release | PR Newswire | +0.92% | +3.35% | |
| Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | Press release | PR Newswire | +0.50% | +1.47% | |
| Insmed to Present at the 2026 Goldman Sachs Annual Global Healthcare Conference | Press release | PR Newswire | +0.24% | -1.30% | |
| Form 8-K INSMED Inc For: May 13 | SEC filing · Form 8-K | SEC EDGAR | -2.12% | -0.20% | |
| Form S-3ASR INSMED Inc | SEC filing · Form S-3ASR | SEC EDGAR | -2.12% | -0.20% | |
| Form 10-Q INSMED Inc For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +5.59% | -10.19% | |
| Form 8-K INSMED Inc For: May 07 | SEC filing · Form 8-K | SEC EDGAR | +5.59% | -10.19% | |
| Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update | Press release | PR Newswire | +5.59% | -10.19% | |
| Insmed and Ty Pennington Team Up to Drive Awareness and Proper Diagnosis of Bronchiectasis | Press release | PR Newswire | +5.59% | -10.19% | |
| Insmed to Present Data Across Its Respiratory Portfolio, Including Late-Breaking ARIKAYCE® Results from Phase 3b ENCORE Study, at the American Thoracic Society International Conference 2026 | Press release | PR Newswire | +3.79% | +4.58% | |
| Insmed to Present at May 2026 Investor Conferences | Press release | PR Newswire | +0.10% | +0.24% | |
| Insmed to Host First-Quarter 2026 Financial Results Conference Call on Thursday, May 7, 2026 | Press release | PR Newswire | +0.29% | -0.45% | |
| Form 8-K INSMED Inc For: Apr 07 | SEC filing · Form 8-K | SEC EDGAR | -3.83% | -1.39% | |
| Insmed Provides Clinical Update on Phase 2b CEDAR Study | Press release | PR Newswire | -3.83% | -1.39% | |
| Form ARS INSMED Inc For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.45% | +0.57% | |
| Form DEF 14A INSMED Inc For: May 13 | SEC filing · Form DEF | SEC EDGAR | +0.45% | +0.57% | |
| Form DEFA14A INSMED Inc | SEC filing · Form DEFA14A | SEC EDGAR | +0.45% | +0.57% | |
| Form 8-K INSMED Inc For: Mar 23 | SEC filing · Form 8-K | SEC EDGAR | +0.41% | -2.13% | |
| Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease | Press release | PR Newswire | +0.41% | -2.13% | |
| Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | Press release | PR Newswire | -0.70% | -3.02% | |
| Form 10-K INSMED Inc For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -3.75% | +4.70% | |
| Form 8-K INSMED Inc For: Feb 17 | SEC filing · Form 8-K | SEC EDGAR | -3.75% | +4.70% | |
| Insmed Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Business Update | Press release | PR Newswire | -3.75% | +4.70% | |
| Insmed To Present at March 2026 Investor Conferences | Press release | PR Newswire | -0.11% | +1.03% | |
| Insmed to Host Fourth-Quarter and Full-Year 2025 Financial Results Conference Call on Thursday, February 19, 2026 | Press release | PR Newswire | +0.71% | -0.93% | |
| Insmed to Present Multiple Abstracts on Treprostinil Palmitil Inhalation Powder (TPIP) at Pulmonary Vascular Research Institute (PVRI) 2026 Congress | Press release | PR Newswire | +0.68% | -4.02% | |
| Form 8-K INSMED Inc For: Jan 09 | SEC filing · Form 8-K | SEC EDGAR | -1.36% | -5.49% | |
| Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference | Press release | PR Newswire | -1.36% | -5.49% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Insmed Incorporated (INSM) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | -0.10% | -0.17% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Insmed Incorporated (INSM) Shareholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.06% | +3.21% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Insmed Incorporated (INSM) And Encourages Shareholders to Connect | Press release | ACCESS Newswire | -1.92% | -0.52% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Insmed Incorporated (INSM) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.02% | +1.30% | |
| Insmed To Present at the 44th Annual J.P. Morgan Healthcare Conference | Press release | PR Newswire | -0.69% | +0.76% | |
| Insmed Incorporated (INSM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.04% | -0.27% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the INSM section they belong to.
Where else INSM is measured.
INSM earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Synthetic Biologics, Inc. (SYN) | 703 | -0.34% | 41% |
| PishPosh, Inc. (BABY) | 702 | 0.00% | 48% |
| Revance Therapeutics, Inc. (RVNC) | 701 | 0.00% | 42% |
| AB Corporate Bond ETF (EYEG) | 700 | 0.00% | 44% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Insmed Incorporated's median reaction calculated?
Every labeled INSM news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 701 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 45% of INSM's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does INSM's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.